Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME SODIUM versus ZINACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME SODIUM versus ZINACEF.
CEFUROXIME SODIUM vs ZINACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime sodium is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cefuroxime, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
750 mg to 1.5 g IV or IM every 8 hours; maximum 6 g per day.
750 mg IV/IM every 8 hours; for severe infections: 1.5 g IV every 8 hours; for life-threatening infections: 1.5 g IV every 6 hours
None Documented
None Documented
Terminal elimination half-life: 1.2 hours (range 1-2 hours) in patients with normal renal function; prolonged to 15-22 hours in end-stage renal disease (CrCl <10 mL/min); dosing adjustment required for CrCl <30 mL/min
Terminal elimination half-life: 1.5-2 hours in adults with normal renal function; prolonged to 2.5-3.5 hours in elderly and up to 48 hours in end-stage renal disease.
Renal (95% unchanged via glomerular filtration and tubular secretion); biliary/fecal (minimal, <5%)
Renal: 80-95% unchanged via glomerular filtration and tubular secretion; biliary: 5-10% excreted in feces; fecal: negligible.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic